Cellebrite DI Ltd.

NasdaqGS:CLBT Voorraadrapport

Marktkapitalisatie: US$3.9b

Cellebrite DI Balans Gezondheid

Financiële gezondheid criteriumcontroles 6/6

Cellebrite DI heeft een totaal eigen vermogen van $298.3M en een totale schuld van $0.0, wat de schuld-eigenvermogensverhouding op 0% brengt. De totale activa en totale passiva bedragen respectievelijk $629.2M en $330.9M. De EBIT Cellebrite DI is $56.2M waardoor de rentedekking 0.2 is. Het heeft contanten en kortetermijnbeleggingen van $370.8M.

Belangrijke informatie

0%

Verhouding schuld/eigen vermogen

US$0

Schuld

Rente dekkingsratio0.2x
ContantUS$370.76m
AandelenUS$298.32m
Totaal verplichtingenUS$330.93m
Totaal activaUS$629.25m

Recente financiële gezondheidsupdates

Geen updates

Recent updates

Cellebrite: There Are Potential Risks That Could Damper Growth

Nov 08

Is There Now An Opportunity In Cellebrite DI Ltd. (NASDAQ:CLBT)?

Oct 30
Is There Now An Opportunity In Cellebrite DI Ltd. (NASDAQ:CLBT)?

There Could Be A Chance Cellebrite DI Ltd.'s (NASDAQ:CLBT) CEO Will Have Their Compensation Increased

Sep 10
There Could Be A Chance Cellebrite DI Ltd.'s (NASDAQ:CLBT) CEO Will Have Their Compensation Increased

Cellebrite: Rating Downgrade As Valuation Has Caught Up

Aug 27

Cellebrite DI Ltd.'s (NASDAQ:CLBT) 29% Share Price Surge Not Quite Adding Up

Aug 17
Cellebrite DI Ltd.'s (NASDAQ:CLBT) 29% Share Price Surge Not Quite Adding Up

Why We're Not Concerned About Cellebrite DI Ltd.'s (NASDAQ:CLBT) Share Price

Jun 25
Why We're Not Concerned About Cellebrite DI Ltd.'s (NASDAQ:CLBT) Share Price

Is Cellebrite DI Ltd. (NASDAQ:CLBT) Potentially Undervalued?

May 21
Is Cellebrite DI Ltd. (NASDAQ:CLBT) Potentially Undervalued?

Cellebrite: Big Fish In A Small Pond

Apr 29

Cellebrite DI Ltd.'s (NASDAQ:CLBT) P/S Is Still On The Mark Following 28% Share Price Bounce

Mar 14
Cellebrite DI Ltd.'s (NASDAQ:CLBT) P/S Is Still On The Mark Following 28% Share Price Bounce

Cellebrite DI Ltd. (NASDAQ:CLBT) Released Earnings Last Week And Analysts Lifted Their Price Target To US$13.17

Feb 18
Cellebrite DI Ltd. (NASDAQ:CLBT) Released Earnings Last Week And Analysts Lifted Their Price Target To US$13.17

There's Reason For Concern Over Cellebrite DI Ltd.'s (NASDAQ:CLBT) Price

Jan 28
There's Reason For Concern Over Cellebrite DI Ltd.'s (NASDAQ:CLBT) Price

Is Cellebrite DI Ltd. (NASDAQ:CLBT) Trading At A 39% Discount?

Nov 04
Is Cellebrite DI Ltd. (NASDAQ:CLBT) Trading At A 39% Discount?

Calculating The Intrinsic Value Of Cellebrite DI Ltd. (NASDAQ:CLBT)

May 26
Calculating The Intrinsic Value Of Cellebrite DI Ltd. (NASDAQ:CLBT)

We Ran A Stock Scan For Earnings Growth And Cellebrite DI (NASDAQ:CLBT) Passed With Ease

Apr 29
We Ran A Stock Scan For Earnings Growth And Cellebrite DI (NASDAQ:CLBT) Passed With Ease

Is Now The Time To Look At Buying Cellebrite DI Ltd. (NASDAQ:CLBT)?

Mar 16
Is Now The Time To Look At Buying Cellebrite DI Ltd. (NASDAQ:CLBT)?

Cellebrite DI Ltd. (NASDAQ:CLBT) Held Back By Insufficient Growth Even After Shares Climb 33%

Feb 16
Cellebrite DI Ltd. (NASDAQ:CLBT) Held Back By Insufficient Growth Even After Shares Climb 33%

Is There An Opportunity With Cellebrite DI Ltd.'s (NASDAQ:CLBT) 45% Undervaluation?

Feb 09
Is There An Opportunity With Cellebrite DI Ltd.'s (NASDAQ:CLBT) 45% Undervaluation?

Analyse van de financiële positie

Kortlopende schulden: De korte termijn activa ( $501.5M ) CLBT } overtreffen de korte termijn passiva ( $272.9M ).

Langlopende schulden: De kortetermijnactiva CLBT ( $501.5M ) overtreffen de langetermijnschulden ( $58.0M ).


Schuld/ eigen vermogen geschiedenis en analyse

Schuldniveau: CLBT is schuldenvrij.

Schuld verminderen: CLBT heeft de afgelopen 5 jaar geen schulden gehad.


Balans


Analyse van de cashflow

Voor bedrijven die in het verleden gemiddeld verliesgevend zijn geweest, beoordelen we of ze ten minste 1 jaar kasstroom hebben.

Stabiele cash runway: Terwijl het verlieslatende CLBT voldoende cash runway heeft voor meer dan 3 jaar, als het zijn huidige positieve vrije kasstroom-niveau behoudt.

Voorspelling contante baan: CLBT is verlieslatend, maar heeft voldoende kasmiddelen voor meer dan 3 jaar, omdat de vrije kasstroom positief is en met 30.3 % per jaar groeit.


Ontdek gezonde bedrijven